Business Context and Reporting Period
Company: Phibro Animal Health Corporation (PAHC)
Filing Type: Form 8-K (Current Report)
Date of Report: October 31, 2024
Event: Completion of a strategic acquisition and associated financing.
Key Financial Metrics and Transaction Details
- Acquisition Price: $350 million in cash (subject to adjustments).
- Target Assets: Medicated feed additive (MFA) product portfolio, certain water-soluble products, and related assets from Zoetis Inc.
- Financing Structure: $350 million borrowed under the Company's Credit Agreement dated July 3, 2024.
- Loan Composition:
- $189 million in Delayed Draw Term A-1 Loans.
- $161 million in Delayed Draw Term A-2 Loans.
- Financial Statements: Pro forma financial information is not included in this filing; an amendment is expected within 71 calendar days.
Material Changes
The primary material change is the expansion of Phibro's product portfolio through the acquisition of Zoetis's MFA assets. Concurrently, the Company's debt obligations increased by $350 million to fund the transaction. No prior period comparative financial data is provided in this specific filing.
Outlook, Risks, and Management Commentary
- Management Action: The Company issued a press release (Exhibit 99.1) announcing the deal completion.
- Regulatory Disclosure: Information in Item 7.01 is furnished under Regulation FD and is not deemed "filed" under the Exchange Act.
- Future Filings: The Company intends to file an amendment to this 8-K to include required financial statements and pro forma information.
- Risks/Contingencies: The purchase price is subject to adjustments as defined in the Purchase Agreement. Specific risks related to the integration of the acquired assets are not detailed in this text.
Investor Verification Checklist
- Verify the specific purchase price adjustments in the final closing statement.
- Review the upcoming Form 8-K amendment for pro forma financial impact on revenue and earnings.
- Examine the terms of the Credit Agreement (Exhibit 10.2 to the 2024 10-K) for interest rates and covenants related to the new $350 million debt load.
- Confirm the integration timeline and expected synergies from the Zoetis MFA portfolio in future earnings calls or reports.